Clinical trial
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human…
NCT00193063 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193063 |
|---|---|
| Title | Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer |
| Official title | Phase II Trial of Weekly Gemcitabine and Herceptin in the Treatment of Patients With HER-2 Overexpressing Metastatic Breast Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Eli Lilly and Company Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Trastuzumab, Gemcitabine |
| Enrollment | 41 |
| Start date | Jul 1, 2001 |
| Primary completion | May 1, 2009 |
| Completion | Aug 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 12, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: